Risultati per: Raccomandazioni cliniche per il melanoma cutaneo

Iniziativa benefica high-tech mercoledì in Vaticano

This cohort study assesses incidence of primary invasive cutaneous malignant melanoma and mortality trends in Sweden, focusing on the population younger than the mean age of melanoma onset.

Current smokers are more likely to die from their melanoma than never-smokers, while former-smokers appear to have similar risks to never-smokers. Smokers have higher risks of sentinel node-positivity and of complications from node surgery. Study limitations included reliance on self-reporting of smoking status. In only seven studies did patients receive modern systemic therapies, limiting the ability to assess their relative efficacy in smokers and non-smokers.

In Reply We appreciate the thoughtful response by Akama-Garren and Hartman regarding ways of reducing fear of cancer recurrence (FCR) among patients with localized melanoma. They proposed 2 potential solutions: (1) psychological support (which we also proposed) and (2) changing terminology to recategorize melanoma in situ as melanocytic lesions with low risk of progression. In this reply, we discuss both proposals.

To the Editor Mahama et al administered a qualitative survey to assess the fear of cancer recurrence for 51 survivors of localized cutaneous melanoma. The authors found that despite good prognoses, approximately 75% of survivors had fear of cancer recurrence that was negatively associated with their psychological well-being, which, as noted by the authors, aligned with prior studies among patients with melanoma. Surprisingly, Mahama et al observed similar levels of clinical fear of cancer recurrence in patients with stage 0 and stage I to IIA localized cutaneous melanoma despite the fact that patients with stage 0 have a prognosis approaching 100% 5-year melanoma-specific survival. A systematic review of 46 studies found that 82% of survivors of thyroid cancer scored 13 or higher on the Fear of Cancer Recurrence Inventory (FCRI), suggesting that patients with melanoma and thyroid cancer share high levels of cancer worry despite relatively high survival rates compared with other cancers.

Con nivolumab più ipilimumab. Dieci anni fa il tasso di sopravvivenza era al 25% dopo un anno

Dal sistema immunitaria, per contrastare metastasi e recidive

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

Grazie alla combinazione con una molecola.